Abstract: The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer.
Type:
Grant
Filed:
March 15, 2006
Date of Patent:
August 30, 2011
Assignee:
University of Medicine and Dentistry of New Jersey
Abstract: The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therape.
Type:
Grant
Filed:
March 31, 2009
Date of Patent:
August 30, 2011
Assignee:
The Board of Trustees of the Univeristy of Illinois
Abstract: The present invention relates to a crystal structure of PRL-1 (Phospatase of Regenerating Liver) protein and a method of crystallization thereof. It has been found that the PRL-1 protein has a tertiary structure having 5 strands of beta-sheet surrounded by 6 alpha-helices and well-arranged active site with closed P-loop, and monomers form a trimer through farnesylation site in the C-terminus of said protein. Thus intra-cellular migration and membrane localization can be achieved. The said crystal structure of PRL-1 protein of the present invention is very useful for the development the agent which inhibits carcinogenesis and metastasis of the cancer.
Type:
Grant
Filed:
April 26, 2005
Date of Patent:
August 16, 2011
Assignee:
Korea Research Institute of Bioscience and Biotechnology
Inventors:
Seong Eon Ryu, Dae Gwin Jeong, Seung-Jun Kim, Jae Hoon Kim, Jeong Hee Son
Abstract: Compositions and methods for improving renal function with Streptococcus probiotic bacteria selected for converting nitrogenous waste into non-toxic compounds in vivo are provided. By reducing the levels of nitrogenous wastes, the instant compositions reduce kidney burden.
Abstract: The present invention relates to two-component lantibiotics isolated from Bacillus sp. Methods for producing said lantibiotics are provided, wherein dehydration and cyclization of the peptides is carried out by two substrate-specific modifying enzymes. Given the antimicrobial activity of the instant lantibiotics, methods for preventing or treating bacterial infections are also provided.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
July 26, 2011
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Wilfred A. van der Donk, Lisa E. Cooper, Amanda L. McClerren
Abstract: An aqueous textile printing composition is provided having superior printing characteristics that can be used with multicolor rotating screen printing machines without causing environmental problems.
Abstract: The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric A? peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric A? peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric A? peptide assemblies, also known as ADDLs, and ADDL-related assemblies.
Type:
Grant
Filed:
May 11, 2007
Date of Patent:
June 21, 2011
Assignees:
Acumen Pharmaceuticals, Inc., Northwestern University
Inventors:
Wei-Qin Zhao, Grant A. Krafft, William L. Klein
Abstract: The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
Abstract: The present invention is a method for preventing or treating neuropathic pain. Using an agent to decrease the expression or activity of Toll-like receptor 4 (TLR4), behavioral hypersensitivity is attenuated thereby preventing or treating neuropathic pain in a subject in need of such treatment.
Abstract: Methods, systems and kits are provided for detecting and quantifying multiple immunogens in a sample via consecutive addition of quantifiable extenders to immunogen bound complexes of immunogen binding agent attached to a DNA containing an RNA polymerase promoter.
Type:
Grant
Filed:
June 1, 2009
Date of Patent:
May 17, 2011
Assignee:
Trustees of the University of Pennsylvania
Abstract: The present invention is a composition for providing localized delivery of a therapeutic agent to a subject. The instant composition is a hydrophilic matrix-based prodrug system, wherein a protease substrate peptide acts as extracellular protease degradable spacer binding the therapeutic agent to a hydrophilic matrix. Release of the therapeutic agent is achieved by localized activity of extracellular proteases thereby providing minimal toxicity of the therapeutic agent and maximum release with protease activity. Methods for producing the instant composition and providing localized delivery of a therapeutic agent to a subject are also provided.
Type:
Grant
Filed:
November 16, 2007
Date of Patent:
May 17, 2011
Assignee:
The Board of Trustees of the University of Illinois
Abstract: The present invention relates to methods of using a proline/arginine-rich peptide such as PR11 or PR39 for increasing cardiac mass or performance and in the treatment of heart failure.
Abstract: It is intended to provide an antiinflammatory and analgesic preparation for external use whereby side effects of a nonsteroidal antiinflammatory and analgesic drug on the skin can be regulated, the nonsteroidal antiinflammatory and analgesic drug can be prevented from degeneration with time due to a dibenzoylmethane derivative contained as an UV absorbent therein, the dibenzoylmethane derivative can be prevented from crystallization and sedimentation due to an oily phase component contained therein, and the inherent effects of the nonsteroidal anti-inflammatory and analgesic drug can be fully exerted without showing skin irritation caused by the oily phase component, an emulsifier and a thickener.
Abstract: The present invention is a DNA intercalating agent represented by the structure Y—Z—Y, wherein Y is an anti-tumor bis-carbazole and Z is a linear arrangement of multiple aromatic rings, containing at least two aromatic rings, or at least two alicyclic rings, wherein the rings are linked in a 1,4 or 1,3 manner. Methods of inhibiting cancer cells and treating subjects having cancer with these agents are also provided.
Abstract: A patch permitting division of only its release sheet by simply pulling right and left, wherein detachment of the release sheet is easy. There is provided a patch comprising a stretchable support, a plaster applied substantially all over one major surface of the support and a release sheet attached to the whole surface of the plaster wherein only the release sheet is divided at a division zone by simply pulling right and left, and wherein one or two or more precut parts that open when the patch is pulled right and left are disposed in the neighborhood on the division zone.
Abstract: An animal model for chronic pain, and in particular lower back pain, is provided. Methods of identifying agents and reducing chronic pain with identified agents such as methotrexate are also provided.
Abstract: The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis in breast cancer cells by inhibiting the expression or activity of Spot 14. Compositions and methods for treating breast cancer are also provided.
Abstract: Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described.
Type:
Grant
Filed:
June 20, 2007
Date of Patent:
March 15, 2011
Assignees:
St. Jude Children's Research Hospital, The University of North Carolina at Chapel Hill
Inventors:
Philip M. Potter, Monika Weirdl, Matthew R. Redinbo
Abstract: The present invention relates to Mycobacterium avium subspecies paratuberculosis (MAP) as the etiological agent of IBD, including ulcerative colitis and Crohn's disease, as well as Multiple Sclerosis and Alzheimer's Disease. As such, methods for monitoring efficacy of a anti-MAP therapy and determining whether a blood sample is suitable for transfusion are provided based upon presence, absence or amount of MAP nucleic acid.